CDI Labs Services for

Viral Exposure Profiling

VirScan® PhIP-Seq enables researchers to identify viral antibodies created by an individual’s unique history of viral exposures.

REQUEST INFO

Identify Individual’s Unique History of Viral Exposures

With our industry-leading VirScan® Phage ImmunoPrecipitation Sequencing (PhIP-Seq) services

Viral exposing profiling has a wide range of applications in research, clinical, and public health applications. One of its primary uses is in understanding past and present viral infections by identifying viral antibody signatures within a host. This enables researchers to map individual and population-level exposure histories, providing critical insights into epidemiological patterns and the dynamics of infectious diseases.

In clinical practice, viral profiling plays a vital role in diagnosing infections and can also aid in understanding the relationship between viral infections and chronic conditions, such as autoimmune diseases and cancer, by identifying potential triggers or contributing factors.

In research settings, viral profiling contributes to a deeper understanding of host-pathogen interactions and the immune system’s response to viral challenges. This knowledge can drive the development of novel therapeutics and inform strategies to mitigate the impact of viral diseases, making viral profiling a cornerstone of modern virology and immunology.

In global health, viral profiling can enable the tracking of zoonotic spillover events and emerging pathogens, enhancing pandemic preparedness and response. Its ability to monitor viral exposure trends in populations makes it an essential tool for designing targeted public health interventions.

Featured Publication

Human virome profiling identified CMV as the major viral driver of a high accumulation of senescent CD8+ T cells in patients with advanced NSCLC

Marie Naigeon, Nathalie Chaput, et. al.

Abstract

Chronic viral infections accelerate immune aging, especially T cell compartment, which can acquire senescence-associated markers. To explore the association between a patient’s viral history and senescent CD8+ T cells, VirScan technology was used to profile human virome epitope-level antiviral antibodies using the serum of 176 patients with aNSCLC. Virome profiling identified cytomegalovirus (CMV) as the only virus associated with T8sen. CMV was necessary but not sufficient to explain high accumulation of T8sen (T8senhigh status). In CMV+ patients, the proportion of T8sen cells increased with cancer progression. Last, CMV-induced T8senhigh phenotype but not CMV seropositivity itself was associated with worse progression-free and overall survival in patients treated with anti–PD-(L)1 therapy but not with chemotherapy.

VIEW PAPER

CDI Labs Advantages

The most comprehensive protein collections available allow for rapid proteome wide antibody repertoire analysis and target identification studies.
HuProt™ Proteome Microarrays provide high quality, reproducible results with a protein purification process that only selects properly folded proteins.
GMP/GLP compliant workflows and highly trained technicians ensure the highest quality results. Compliant data management processes ensure data integrity and security.
Cutting-edge synthetic biology platforms and an innovative team with deep proteomics bench expertise make CDI Labs an ideal CRO partner for even your most challenging projects.

PhiP-Seq Sample Requirements

Serum or plasma

20 μL aliquot per sample

Cerebrospinal fluid (CSF)

250 μL aliquot per sample

Other antibodies (IgG monoclonals, B cell supernatants, etc)

250 μL aliquot per sample (0.1 mg/mL concentration)

12 sample minimum

In multiples of x12 samples (i.e., x12, x24, x36, 48x – full rows of a standard 96-well plate), and any number after 48 samples